AstraZeneca Annual Report and Form 20-F Information 2011

Directors’ interests in sharesBeneficial interestsThe table below shows any change in the interests of the Directors (including the interests of their Connected Persons, as such term is definedin the Financial Services and Markets Act 2000) in Ordinary Shares from 1 January 2011 to 31 December 2011 or on the date of resignation ofsuch Director (if earlier). All such interests were beneficial except as otherwise stated. However, interests in Ordinary Shares or ADSs that are thesubject of PSP Share Awards, AZIP Share Awards and/or the Deferred Bonus Plan discussed in this Report, are not included in the table belowbut are shown in the Performance Share Plan, AstraZeneca Investment Plan and Deferred Bonus Plan tables from page 126. No Director orsenior executive beneficially owns, or has options over, 1% or more of the issued share capital of the Company, nor do they have different votingrights from other shareholders. None of the Directors has a beneficial interest in the shares of any of the Company’s subsidiaries. Between31 December 2011 and 2 February 2012, there was no change in the interests in Ordinary Shares shown in the table below.Beneficial interestin OrdinaryShares at1 January 2011 or(if later) appointment dateChange to beneficialinterestBeneficial interestin OrdinaryShares at31 December 2011 or(if earlier) resignation dateLouis Schweitzer 16,615 – 16,615David Brennan 186,982 59,192 246,174Simon Lowth 9,346 44,880 54,226Bruce Burlington 553 – 553Jean-Philippe Courtois 2,635 – 2,635Jane Henney 1 1,314 – 1,314Michele Hooper 2,400 – 2,400Rudy Markham 1,940 512 2,452Nancy Rothwell 1,314 518 1,832Shriti Vadera 3,000 – 3,000John Varley 1,294 450 1,744Marcus Wallenberg 63,646 – 63,6461Ceased to be a Director on 28 April 2011.Unitised stock plansDavid Brennan, in common with other participating executives in the US, has interests in the following plans which were awarded to himprior to him becoming CEO: the AstraZeneca Executive Deferral Plan, the AstraZeneca Executive Deferred Compensation Plan and theAstraZeneca Savings and Security Plan. These are unitised stock plans into which the value of certain previous share incentive awards hasbeen deferred (and are not incentive awards in their own right). Participants hold units in each plan, which represent a long-term equity interestin the Company. A unit comprises part cash and part ADSs. The overall unit value can be determined daily by taking the market value ofthe underlying ADSs and adding the cash position. The ADSs held within these units carry both voting and dividend rights. David Brennanis deemed to have a notional beneficial interest in these ADSs, calculated by reference to the fund value and the closing price of ADSs.Therefore, the number of ADSs in which a notional beneficial interest arises can vary daily as a consequence of stock price movements.Unitised stock planADSs held at1 January 2011Net ADSs acquiredduring 2011ADSs heldat 31 December 2011AstraZeneca Executive Deferral Plan 37,741 2,261 40,002AstraZeneca Savings and Security Plan 8,523 499 9,022Corporate GovernanceAstraZeneca Annual Report and Form 20-F Information 2011Directors’ Remuneration Report 125